Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03541850 · ClinicalTrials.gov registry record · Phase 2

Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

A Phase 2 study of PSA Progression and Stage III Prostate Adenocarcinoma AJCC v7, sponsored by Jonsson Comprehensive Cancer Center.

Active
Registry status
Phase 2
Development phase
92
Enrollment target
2
Study locations

NCT03541850 is a Phase 2 study of PSA Progression and Stage III Prostate Adenocarcinoma AJCC v7 that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 92 participants, below the 268-participant average among 5 other PSA Progression trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03541850, a Phase 2 study of PSA Progression and Stage III Prostate Adenocarcinoma AJCC v7, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
92 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial studies how well stereotactic body radiation therapy works in treating patients with prostate cancer that has not spread to other parts of the body and have undergone surgery. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue.

Conditions Studied

PSA Progression Stage III Prostate Adenocarcinoma AJCC v7 Stage II Prostate Adenocarcinoma AJCC v7 PSA Level Greater Than 0.03 Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7

Interventions

  • OTHER Quality-of-Life Assessment
  • RADIATION Stereotactic Body Radiation Therapy
  • DRUG Antiandrogen Therapy

Study Locations (2)

California

  • USC Norris Comprehensive Cancer Center and Hospital - Los Angeles
  • UCLA / Jonsson Comprehensive Cancer Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2019-01-29
Est. Completion 2027-11-01
Phase Phase 2

Sponsor

Jonsson Comprehensive Cancer Center

321 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03541850

The ClinicalTrials.gov registry entry for NCT03541850 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 268-participant average among 5 other PSA Progression trials with a reported enrollment target (66% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with PSA Progression appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.

NCT03541850 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03541850 about?

NCT03541850 is a clinical study titled "Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery". This phase II trial studies how well stereotactic body radiation therapy works in treating patients with prostate cancer that has not spread to other parts of the body and have undergone surgery. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the...

What is the current status of trial NCT03541850?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2019-01-29. Estimated completion is 2027-11-01.

What conditions does trial NCT03541850 study?

This clinical trial studies the following conditions: PSA Progression, Stage III Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, PSA Level Greater Than 0.03, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7.

What interventions are being tested in trial NCT03541850?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Stereotactic Body Radiation Therapy (RADIATION), Antiandrogen Therapy (DRUG).

Who is sponsoring clinical trial NCT03541850?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03541850 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for PSA Progression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

PSA Progression

All registered trials for this condition

Stage III Prostate Adenocarcinoma AJCC v7

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.